392
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Use of breath-actuated inhalers in patients with asthma and COPD – an advance in inhalational therapy: a systematic review

, &

References

  • Hess DH. Aerosol delivery devices in the treatment of asthma. Respir. Care. 53, 699–723 (2008).
  • Pedersen S, Dubus JC, Crompton G, on behalf of the ADMIT Working Group the ADMIT series – Issues in Inhalation Therapy. Inhaler selection in children with asthma. Prim. Care Respir. J. 19, 209–216 (2010).
  • Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin. Allergy 6, 1–6 (1976).
  • Fergusson RJ, Lenney J, McHardy GJ, Crompton GK. The use of a new breath-actuated inhaler by patients with severe airflow obstruction. Eur. Respir. J. 4, 172–174 (1991).
  • Tashkin DP. New devices for asthma. J. Allergy Clin. Immunol. 101, S409–416 (1998).
  • Baum EA, Bryant AM. The development and laboratory testing of a novel breath-actuated pressurised inhaler. J. Internat. Soc. Aerosols. 2, 219 (1988).
  • Ganderton D. General factors influencing drug delivery to the lung. Respir. Med. 91(Suppl. A) 13–16 (1997).
  • Newman SP. Principles of metered-dose inhaler design. Respir. Care 50, 1177–1190 (2005).
  • Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation and performance. Respir. Med. 96, 293–304 (2002).
  • Bronsky EA, Debelic M, Jean-Claude, Hahn M. Ease-of-Use Study of Pirbuterol Acetate in the Autohaler Actuator in Three Countries: The United States, Germany, and France. J. Asthma 30, 439–443 (1993).
  • Larsen JS, Hahn M, Kochevar JW et al. Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann. Allergy 71, 103–106 (1993).
  • Kelloway JS, Kochevar JW, Sveum RJ, Hahn MA. Evaluation of the Autohaler actuator: the effect of written patient instructions on correct use. J. Asthma 30, 373–379 (1993).
  • Price DB, Pearce L, Powell SR, Shirley J, Sayers MK. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int. J. Clin. Pract. 53, 31–36 (1999).
  • Giraud V, Allaert FA, Magnan A. A prospective observational study of patient training in use of the autohaler inhaler device: the Sirocco study. Eur. Rev. Med. Pharmacol. Sci. 15, 563–570 (2011).
  • Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of ‘drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46, 712–716 (1991).
  • Marshik PL, Larsen JS, Leach CL et al. A novel breath actuated device (Autohaler) consistently actuates during the early phase of inspiration. J. Aerosol. Med. 8, 187–195 (1995).
  • Terzano C, Mannino F. Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and Autohaler. Monaldi Arch. Chest Dis. 51, 236–242 (1996).
  • Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm. Pharmacol. Ther. 10, 211–214 (1997).
  • Kamin WE, Genz T, Roeder S et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol. Med. 15, 65–73 (2002).
  • Aswania O, Ritson S, Iqbal SM, Bhatt J, Rigby AS, Everard ML. Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers. J. Aerosol. Med. 17, 231–238 (2004).
  • Crompton G, Duncan J. Clinical assessment of a new breath actuated inhaler. Practitioner 233, 268–269 (1989).
  • Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 104, 1332–1337 (1993).
  • Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. 94, 496–500 (2000).
  • vanSchayck CP, Bijl-Hofland ID, Folgering H et al. Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand. J. Prim. Health Care 20, 126–128 (2002).
  • Steier J, Trammer T, Cloes RM, Zetterstrom O, van den Elshout FJ, Laitinen LA. Optical feedback training of inhalation with autohaler and turbuhaler in COPD patients. Lung 181, 183–192 (2003).
  • Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary Care. J. Aerosol. Med. 16, 249–254 (2003).
  • Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello JY, Giraud V. Improvement of asthma control with beclomethasoneextrafine aerosol compared to fluticasone and budesonide. Respir. Med. 99, 770–778 (2005).
  • Giraud V, Allaert FA. Improved asthma control with breath-actuated pressurized Metered Dose Inhaler (pMDI): the SYSTER survey. Eur. Rev. Med. Pharmacol. Sci. 13, 323–330 (2009).
  • Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 36, 213–218 (2007).
  • Rau JL. Practical Problems with Aerosol Therapy in COPD. Respir. Care 51, 158–172 (2006).
  • Crompton GK. Breath activated aerosol. BMJ 2, 652–653 (1971).
  • Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 41, 118–124 (1986).
  • Pedersen S, Mortensen S. Use of different inhalation devices in children. Lung 168(Suppl.), 653–657 (1990).
  • Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch. Dis. Child 68, 477–480 (1993).
  • Arshad H, Luyt D, Goodwin A, Jones A, Hide D, Williams I. Sodium cromoglycate via inhaler and Autohaler. Respir. Med. 87, 299–302 (1993).
  • Devadason SG, Huang T, Walker S, Troedson R, Le Souëf PN. Distribution of technetium-99 m-labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 21, 1007–1011 (2003).
  • Petersen R, Agertoft L, Pedersen S. Treatment of exercise-induced asthma with beclomethasonedipropionate in children with asthma. Eur. Respir. J. 24, 932–937 (2004).
  • Donnell D. Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device. Eur. Rev. Med. Pharmacol. Sci. 5, 7–16 (2001).
  • Williams DM, Brock TP. Clinical considerations in the use of inhalation delivery devices. J. Pharm. Pract. 14, 277–295 (2001).
  • Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br. J. Dis. Chest 80, 45–49 (1986).
  • Armitage JM, Williams SJ. Inhaler technique in the elderly. Ageing 17, 275–278 (1988).
  • Diggory P, Bailey R, Vallon A. Effectiveness of inhaled bronchodilator delivery systems for elderly patients. Age Aging 20, 379–382 (1991).
  • Arthur V, Pushkin S, Emery P. Inhaler use in patients with arthritic hands. Clin. Trials Meta Anal. 28, 23–28 (1992).
  • Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing 28,481–484 (1999).
  • Langley PC. The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. Clin. Ther. 21, 236–252 (1999).
  • Anandan C, Nurmatov U, van Schayck OC, Sheikh. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 65, 152–167 (2010).
  • Bousquet J, Bousquet PJ, Godard P, Daures JP. “The public health implications of asthma.” Bull. World Health Organ. 83(7), 548–554 (2005).
  • Kelloway JS, Wyatt RA. A cost-effectiveness analysis of breath-actuated metered-dose inhalers. Manag. Care Interface 10, 99–107 (1997).
  • Haycox A, Mitchell G, Niziol C, Featherstone R. Cost effectiveness of asthma treatment with a breath-actuated pressurised metered dose inhaler (BAI) - a prescribing claims study of 1856 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. J. Med. Econ. 5, 66–77 (2002).
  • Haycox A, Mota RM, Featherstone R. Evaluating the cost effectiveness of asthma inhaler systems: an observational study of patients in General Practice in the UK. J. Med. Econ. 10, 297–308 (2007).
  • Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respir. Med. 97, 12–19 (2003).
  • Haycox A, Featherstone R. Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed? J. Med. Econ. 11, 525–539 (2008).
  • Laube BL, Janssens HM, de Jongh FH et al. European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 37, 1308–1331 (2011).
  • Völkl KP, Kroll VM, Wiesemann HG, Schneider B. Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. Arzneimittelforschung 41, 533–536 (1991).
  • Waterhouse JC, Simmons JL, Wray H, Howard P. Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction. Respiration 59, 155–158 (1992).
  • Woodman K, Bremner P, Burgess C, Crane J, Pearce N, Beasley R. A comparative study of the efficacy of beclomethasonedipropionate delivered from a breath activated and conventional metered dose inhaler in asthmatic patients. Curr. Med. Res. Opin.13, 61–69 (1993).
  • Schecker MH, Wilson AF, Mukai DS, Hahn M, Crook D, Novey HS. A device for overcoming discoordination with metered-dose inhalers. J. Allergy Clin. Immunol. 92, 783–789 (1993).
  • Reichel W, Dahl R, Ringdal N et al. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int. J. Clin. Pract. 55, 100–106 (2001).
  • Gross G, Cohen RM, Guy H. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. J. Asthma 40, 487–495 (2003).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.